http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2225207-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate | 1999-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f3697e8c367871855bfc54463653d63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a53c25fc57fc333d8d75ab345de3e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4856bbcedfb42b9eef097db8a407f58b |
| publicationDate | 2004-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2225207-C2 |
| titleOfInvention | Three-phase oral contraceptive |
| abstract | FIELD: medicine. SUBSTANCE: invention describes the contraception method wherein estrogen and progestogen are administrated every day in tree-phase sequence for 21 day. On the first phase the combination of estrogen and progestogen is administrated for 5-8 days in low but effective for contraception every day dose corresponding by estrogenic activity to 23-28 mcg of 17α-ethinylestradiol and by progestogenic activity to 0.065-0.75 mg of norethindrone followed by administration the same dose of estrogen and dose of progestogen for 7-11 days corresponding by progestogenic activity to 0.25-1.0 mg of norethindrone followed by administration the same dose estrogen and dose of progestogen for 3-7 days corresponding by progestogenic activity to 0.35-2.0 mg of norethindrone and the following breaking in administration of both estrogen and progestogen for 4-8 days. EFFECT: expanded assortment of contraceptive agents. 27 cl, 5 tbl, 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10022384-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2796919-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11590147-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2479306-C2 |
| priorityDate | 1998-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.